Delivered in conjunction with the Danya Institute at the National Prevention Network Conference on August 17, 2023 in Birmingham, Alabama.

Xylazine is an emerging issue across the United States. This presentation summarizes the available research and data on xylazine use for public health professionals, specifically in the context of broader substance use prevention.

This presentation was delivered at the Integrating Primary and Behavioral Health Care Through the Lens of Prevention Conference on November 15, 2018 in conjunction with the Education Development Center (EDC). Carnevale Associates and EDC present on the changing nature of substance use prevention; the shifting health care landscape; health care payers, payment vehicles and service delivery models; and the implications of health care financing for prevention partnerships at both the individual and population health levels.

This presentation was delivered at the National Prevention Network (NPN) Conference on August 28, 2018 in conjunction with the Education Development Center (EDC). Carnevale Associates and EDC present emerging trends in opioids (including heroin and fentanyl), cocaine, methamphetamine, and marijuana -- particularly in the context of substance use prevention.

This presentation was delivered at the National Prevention Network (NPN) Conference on August 29, 2018 in conjunction with the Education Development Center (EDC). Carnevale Associates and EDC outline the state of cannabis laws at the state and local level, review pros and cons of the regulatory options available to states, consider differences between the tobacco and alcohol models of for-profit regulation, and ultimately review the implications of state-level cannabis legalization for substance use prevention professionals.

Delivered at the 2013 Utah Valley University Conference on Addiction, this presentation examines the non-medical use of prescription drugs and the Office of National Drug Control Policy's (ONDCP) strategies to curtail prescription drug abuse, notably examining Prescription Drug Monitoring Programs (PMPs) and the Drug Enforcement Administration's (DEA) Proposed Rule governing prescription drug takeback programs.